Global Wet Age Related Macular Degeneration (AMD) Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2024

  • receipt Report ID : 160971
  • calendar_today Published On: Apr, 2019
  • file_copy Pages: 119
  • list Pharmaceuticals and Healthcare

Increased disease burden due to rising geriatric population is one of the major factors driving the growth of the global age-related macular degeneration (AMD) market. This market is expected to surpass a valuation of USD 2,200 Mn by the end of 2023. AMD remains a major cause of central visual loss, effecting close to 10% of people older than 65 years and over 25% of people older than 75 years globally.

Scope of the Report:

Increased awareness among people about the condition has influenced the AMD treatment global demand. At the same time, the arrival of off-patent blockbuster drugs is reflecting favorably on the market particularly in third-world countries. This has allowed small-scale drug manufactures to penetrate untapped markets.

The global Wet Age Related Macular Degeneration (AMD) market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Wet Age Related Macular Degeneration (AMD).

Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

This report studies the Wet Age Related Macular Degeneration (AMD) market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Wet Age Related Macular Degeneration (AMD) market by product type and applications/end industries.

Market Segment by Companies, this report covers

Novartis International (Switzerland)

Bayer (Germany)

Acucela (U.S.)

Neurotech Pharmaceuticals (U.S.)

Ophthotech (U.S.)

GlaxoSmithKline (U.S.)

Alimera Sciences (U.S.)

StemCell (Canada)

F. Hoffmann-La Roche (Switzerland)

Regeneron Pharmaceutical (U.S.)

Allergan (Ireland)

Adverum Biotechnologies (U.S.)

Gilead Sciences (U.S.)

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Wet Age-Related Macular Degeneration (Wet AMD)

Dry Age-Related Macular Degeneration (Dry AMD)

Market Segment by Applications, can be divided into

>75 Years 

>60 Years 

>40 Years

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Wet Age Related Macular Degeneration (AMD) Market Overview

1.1 Product Overview and Scope of Wet Age Related Macular Degeneration (AMD)

1.2 Classification of Wet Age Related Macular Degeneration (AMD) by Types

1.2.1 Global Wet Age Related Macular Degeneration (AMD) Revenue Comparison by Types (2017-2023)

1.2.2 Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share by Types in 2017

1.2.3 Wet Age-Related Macular Degeneration (Wet AMD)

1.2.4 Dry Age-Related Macular Degeneration (Dry AMD)

1.3 Global Wet Age Related Macular Degeneration (AMD) Market by Application

1.3.1 Global Wet Age Related Macular Degeneration (AMD) Market Size and Market Share Comparison by Applications (2013-2023)

1.3.2 >75 Years 

1.3.3 >60 Years 

1.3.4 >40 Years

1.4 Global Wet Age Related Macular Degeneration (AMD) Market by Regions

1.4.1 Global Wet Age Related Macular Degeneration (AMD) Market Size (Million USD) Comparison by Regions (2013-2023)

1.4.1 North America (USA, Canada and Mexico) Wet Age Related Macular Degeneration (AMD) Status and Prospect (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy) Wet Age Related Macular Degeneration (AMD) Status and Prospect (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Wet Age Related Macular Degeneration (AMD) Status and Prospect (2013-2023)

1.4.4 South America (Brazil, Argentina, Colombia) Wet Age Related Macular Degeneration (AMD) Status and Prospect (2013-2023)

1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Wet Age Related Macular Degeneration (AMD) Status and Prospect (2013-2023)

1.5 Global Market Size of Wet Age Related Macular Degeneration (AMD) (2013-2023)

2 Manufacturers Profiles

2.1 Novartis International (Switzerland)

2.1.1 Business Overview

2.1.2 Wet Age Related Macular Degeneration (AMD) Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Novartis International (Switzerland) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2016-2017)

2.2 Bayer (Germany)

2.2.1 Business Overview

2.2.2 Wet Age Related Macular Degeneration (AMD) Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Bayer (Germany) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2016-2017)

2.3 Acucela (U.S.)

2.3.1 Business Overview

2.3.2 Wet Age Related Macular Degeneration (AMD) Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Acucela (U.S.) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2016-2017)

2.4 Neurotech Pharmaceuticals (U.S.)

2.4.1 Business Overview

2.4.2 Wet Age Related Macular Degeneration (AMD) Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Neurotech Pharmaceuticals (U.S.) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2016-2017)

2.5 Ophthotech (U.S.)

2.5.1 Business Overview

2.5.2 Wet Age Related Macular Degeneration (AMD) Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Ophthotech (U.S.) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2016-2017)

2.6 GlaxoSmithKline (U.S.)

2.6.1 Business Overview

2.6.2 Wet Age Related Macular Degeneration (AMD) Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 GlaxoSmithKline (U.S.) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2016-2017)

2.7 Alimera Sciences (U.S.)

2.7.1 Business Overview

2.7.2 Wet Age Related Macular Degeneration (AMD) Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 Alimera Sciences (U.S.) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2016-2017)

2.8 StemCell (Canada)

2.8.1 Business Overview

2.8.2 Wet Age Related Macular Degeneration (AMD) Type and Applications

2.8.2.1 Product A

2.8.2.2 Product B

2.8.3 StemCell (Canada) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2016-2017)

2.9 F. Hoffmann-La Roche (Switzerland)

2.9.1 Business Overview

2.9.2 Wet Age Related Macular Degeneration (AMD) Type and Applications

2.9.2.1 Product A

2.9.2.2 Product B

2.9.3 F. Hoffmann-La Roche (Switzerland) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2016-2017)

2.10 Regeneron Pharmaceutical (U.S.)

2.10.1 Business Overview

2.10.2 Wet Age Related Macular Degeneration (AMD) Type and Applications

2.10.2.1 Product A

2.10.2.2 Product B

2.10.3 Regeneron Pharmaceutical (U.S.) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2016-2017)

2.11 Allergan (Ireland)

2.11.1 Business Overview

2.11.2 Wet Age Related Macular Degeneration (AMD) Type and Applications

2.11.2.1 Product A

2.11.2.2 Product B

2.11.3 Allergan (Ireland) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2016-2017)

2.12 Adverum Biotechnologies (U.S.)

2.12.1 Business Overview

2.12.2 Wet Age Related Macular Degeneration (AMD) Type and Applications

2.12.2.1 Product A

2.12.2.2 Product B

2.12.3 Adverum Biotechnologies (U.S.) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2016-2017)

2.13 Gilead Sciences (U.S.)

2.13.1 Business Overview

2.13.2 Wet Age Related Macular Degeneration (AMD) Type and Applications

2.13.2.1 Product A

2.13.2.2 Product B

2.13.3 Gilead Sciences (U.S.) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2016-2017)

3 Global Wet Age Related Macular Degeneration (AMD) Market Competition, by Players

3.1 Global Wet Age Related Macular Degeneration (AMD) Revenue and Share by Players (2013-2018)

3.2 Market Concentration Rate

3.2.1 Top 5 Wet Age Related Macular Degeneration (AMD) Players Market Share

3.2.2 Top 10 Wet Age Related Macular Degeneration (AMD) Players Market Share

3.3 Market Competition Trend

4 Global Wet Age Related Macular Degeneration (AMD) Market Size by Regions

4.1 Global Wet Age Related Macular Degeneration (AMD) Revenue and Market Share by Regions

4.2 North America Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2013-2018)

4.3 Europe Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2013-2018)

4.4 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2013-2018)

4.5 South America Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2013-2018)

4.6 Middle East and Africa Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2013-2018)

5 North America Wet Age Related Macular Degeneration (AMD) Revenue by Countries

5.1 North America Wet Age Related Macular Degeneration (AMD) Revenue by Countries (2013-2018)

5.2 USA Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2013-2018)

5.3 Canada Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2013-2018)

5.4 Mexico Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2013-2018)

6 Europe Wet Age Related Macular Degeneration (AMD) Revenue by Countries

6.1 Europe Wet Age Related Macular Degeneration (AMD) Revenue by Countries (2013-2018)

6.2 Germany Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2013-2018)

6.3 UK Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2013-2018)

6.4 France Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2013-2018)

6.5 Russia Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2013-2018)

6.6 Italy Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2013-2018)

7 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Revenue by Countries

7.1 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Revenue by Countries (2013-2018)

7.2 China Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2013-2018)

7.3 Japan Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2013-2018)

7.4 Korea Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2013-2018)

7.5 India Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2013-2018)

7.6 Southeast Asia Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2013-2018)

8 South America Wet Age Related Macular Degeneration (AMD) Revenue by Countries

8.1 South America Wet Age Related Macular Degeneration (AMD) Revenue by Countries (2013-2018)

8.2 Brazil Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2013-2018)

8.3 Argentina Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2013-2018)

8.4 Colombia Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2013-2018)

9 Middle East and Africa Revenue Wet Age Related Macular Degeneration (AMD) by Countries

9.1 Middle East and Africa Wet Age Related Macular Degeneration (AMD) Revenue by Countries (2013-2018)

9.2 Saudi Arabia Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2013-2018)

9.3 UAE Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2013-2018)

9.4 Egypt Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2013-2018)

9.5 Nigeria Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2013-2018)

9.6 South Africa Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2013-2018)

10 Global Wet Age Related Macular Degeneration (AMD) Market Segment by Type

10.1 Global Wet Age Related Macular Degeneration (AMD) Revenue and Market Share by Type (2013-2018)

10.2 Global Wet Age Related Macular Degeneration (AMD) Market Forecast by Type (2018-2023)

10.3 Wet Age-Related Macular Degeneration (Wet AMD) Revenue Growth Rate (2013-2023)

10.4 Dry Age-Related Macular Degeneration (Dry AMD) Revenue Growth Rate (2013-2023)

11 Global Wet Age Related Macular Degeneration (AMD) Market Segment by Application

11.1 Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share by Application (2013-2018)

11.2 Wet Age Related Macular Degeneration (AMD) Market Forecast by Application (2018-2023)

11.3 >75 Years  Revenue Growth (2013-2018)

11.4 >60 Years  Revenue Growth (2013-2018)

11.5 >40 Years Revenue Growth (2013-2018)

12 Global Wet Age Related Macular Degeneration (AMD) Market Size Forecast (2018-2023)

12.1 Global Wet Age Related Macular Degeneration (AMD) Market Size Forecast (2018-2023)

12.2 Global Wet Age Related Macular Degeneration (AMD) Market Forecast by Regions (2018-2023)

12.3 North America Wet Age Related Macular Degeneration (AMD) Revenue Market Forecast (2018-2023)

12.4 Europe Wet Age Related Macular Degeneration (AMD) Revenue Market Forecast (2018-2023)

12.5 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Revenue Market Forecast (2018-2023)

12.6 South America Wet Age Related Macular Degeneration (AMD) Revenue Market Forecast (2018-2023)

12.7 Middle East and Africa Wet Age Related Macular Degeneration (AMD) Revenue Market Forecast (2018-2023)

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source

List of Tables and Figures

Figure Wet Age Related Macular Degeneration (AMD) Picture

Table Product Specifications of Wet Age Related Macular Degeneration (AMD)

Table Global Wet Age Related Macular De

Please fill the form below, to recieve the report sample


+1